MTD
Mettler-Toledo International Inc.1386.45
-26.02-1.84%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Q&A details Q1 caution, FY ramp
Q&A unpacked the FY2026 guide's components, showing Q1 local currency sales up ~3% with pricing at 3.5%, acquisitions ~1%, but organic volumes down 1.5% from customer caution despite better headlines—ramping gradually to 1% FY organic volume. Segment details emerged: core industrial flat Q1 (low-mid FY), product inspection mid-high single Q1 (low-mid FY, innovation-driven not recovery), service mid-high single FY toward $3B installed base. China pharmacopeia aids steadily, onshoring '27+. Tariffs mitigated, Swiss relief aids margins. Q1 stays cautious. Investors eye order momentum.
Key Stats
Market Cap
28.56BP/E (TTM)
34.60Basic EPS (TTM)
40.07Dividend Yield
0%Recent Filings
10-K
FY2025 results
Mettler-Toledo posted $4.0B in FY2025 net sales, up 4% reported and 3% local currency, with Q4 delivering 27-30% of the annual total per historical seasonality while service revenue surged 8% amid soft end-markets. Laboratory sales (56% of total) edged up 3% reported but industrial (39%) accelerated 6%, fueled by product inspection strength and pricing gains that offset $50M tariff hits and squeezed gross margins to 59.4%. Yet cash from operations topped $955M, funding $800M in buybacks of 647K shares at $1,237 average. Debt stands at $2.2B with $536M revolver room. China risks loom large.
8-K
Q4 sales +8%, adjusted EPS +8%
Mettler-Toledo reported Q4 sales up 8% to $1.130 billion on February 5, 2026, with local currency growth of 5% including 1% from acquisitions. Adjusted EPS rose 8% to $13.36, while full-year adjusted EPS grew 4% to $42.73 amid softer Europe and Asia. Q1 2026 local currency sales eyed at 3%; full-year adjusted EPS at $46.05-$46.70. Strong cash flow persists.
8-K
Tokich joins MTD board
Mettler-Toledo appointed Michael J. Tokich, former STERIS CFO with 17+ years' experience, to its board effective February 5, 2026, expanding from nine to ten directors. An independent director, Tokich brings financial acumen, operational savvy, and IT insights. Board chair praises his growth track record. No committee assignments yet.
10-Q
Q3 FY2025 results
Mettler-Toledo posted Q3 sales of $1.0B, up 8% y/y, with products +7% and service +10%; gross margin slipped to 59.2% from 60.0% on tariff costs, yet operating momentum held as earnings before taxes rose 4% y/y to $269M. Diluted EPS climbed to $10.57 from $9.96 on share repurchases shrinking weighted shares to 20.6M; YTD net earnings dipped to $583M from $611M, tax rate up to 18.9% from 15.5% sans prior discrete benefit. Cash swelled to $69M, revolver shows $472M available despite $2.2B total debt; Q3 deals cost $72.6M cash (up to $31.2M contingent), added $48.4M goodwill and $30.3M customer intangibles over 5-10 years. Free cash flow not disclosed in the 10-Q. Tariffs pressure margins.
8-K
Q3 sales up 8%, Adjusted EPS +9%
Mettler-Toledo reported Q3 sales up 8% to $1,029.7M on USD basis, 6% in local currency, with Adjusted EPS rising 9% to $11.15. Industrial drove strong growth while Asia/RoW lagged. Board added $2.75B to share repurchases. Q4 local currency sales to grow ~3%; full-year Adjusted EPS $42.05-$42.25, but tariffs hit hard.
A
Agilent Technologies, Inc.
139.19-1.41
BDX
Becton, Dickinson and Company
196.39-3.70
BIO
Bio-Rad Laboratories, Inc.
302.02-5.90
DGX
Quest Diagnostics Incorporated
178.66-5.45
DHR
Danaher Corporation
224.70-3.83
IDXX
IDEXX Laboratories, Inc.
693.18-6.95
ILMN
Illumina, Inc.
131.56-3.36
MLAB
Mesa Laboratories, Inc.
78.63+0.80
TMO
Thermo Fisher Scientific Inc
570.16-5.75
WAT
Waters Corporation
378.53-6.89